AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00286624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
Study NCT00286624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
Study NCT00286624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
Study NCT01947335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided PCI
Description: Intravascular ultrasound guided percutaneous coronary intervention
Study NCT01798147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB TACE
Description: DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
Study NCT01798147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
Study NCT00852579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Daily dose 250mg
Study NCT00852579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00728156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
Study NCT00728156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
Study NCT01444001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: 0.5 mL, intramuscular
Study NCT00920738 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
Study NCT03549468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level tragus stimulation
Description: All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
Study NCT04009460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
Study NCT01158066 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: CT Cardiac
Description: the patient will undergo cardiac CT
Study NCT01852630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime + Albumin
Description: cefepime + Albumin will be given for 2 days
Study NCT01852630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Albumin
Description: Imipenem + Albumin will be given for 2 days.
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in children (24 months-5 years old)
Description: 0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
Study NCT02086903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
Study NCT02086903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Description: The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
Study NCT04167293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
Study NCT04167293 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
Study NCT04167293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
Study NCT04657926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APPA
Description: APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
Study NCT04657926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT03865186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Program
Description: The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks.
Study NCT03865186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no intervention
Study NCT02865252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MWM Treatment
Study NCT02865252 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MWM Sham
Study NCT02275130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxyapatite
Description: Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
Study NCT02275130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse Voice (Calcium Hydroxyapatite)
Study NCT00937482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00937482 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Undergo whole-brain radiotherapy
Study NCT03607526 — intervention group
Intervention type: OTHER
Intervention: Barriers
Description: NGT sessions identifying barriers to vegetable intake.
Study NCT03607526 — intervention group
Intervention type: OTHER
Intervention: Facilitators
Description: NGT sessions identifying facilitators to vegetable intake.
Study NCT00296634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant at 1200 mcg/mL.
Study NCT00296634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
Study NCT04221139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality games
Description: Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
Study NCT02086630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart
Study NCT03166423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MU001 patches (Investigational)
Description: Patches containing snail slime, calendula extract and propolis extract
Study NCT03166423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional patches (Control)
Description: Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
Study NCT02714517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrotherapy
Description: 30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
Study NCT02714517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: on land therapy
Description: 30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
Study NCT04183075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FontActiv Superprotein/Hypercaloric Fiber
Description: The product under study has a liquid presentation, in 200 ml bottles, ready to take
Study NCT04183075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates and C Vitamin
Description: The control product will be prepared with equal presentation and taste as similar as possible tan study product
Study NCT03456154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: 60u will be used at 3 sites of masseter muscle, on each side of the face
Study NCT03456154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
Study NCT03850951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual appliances
Description: Patients with moderate crowding will be treated without extraction using lingual appliances.
Study NCT03850951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labial appliances
Description: Patients with moderate crowding will be treated without extraction using labial appliances.
Study NCT05898191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal laser treatment
Description: non-ablative vaginal laser application
Study NCT04511767 — intervention group
Intervention type: OTHER
Intervention: Do not take any interventions
Description: Do not take any interventions
Study NCT03415360 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoablation
Description: cryoablation of nerve responsible for phantom limb pain
Study NCT05409469 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: surgery on patients with aortic dissection
Study NCT04015011 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LCD Intervention
Description: composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
Study NCT00703742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: A,1: Escitalopram, oral, 20 mg/day, 8 weeks
Study NCT04739930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation
Description: Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
Study NCT04739930 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group incision
Description: 0.5cm sham incision over the iliac crest
Study NCT00868829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird2
Description: For the patient participated, only Firebird2 Stent will be implanted.
Study NCT05408273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device
Description: We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
Study NCT02025803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114/capecitabine
Description: Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).
Study NCT01620450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Study NCT01620450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Study NCT02846051 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: venous mapping
Description: clinical examination + doppler echo
Study NCT02030587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Study NCT02030587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Adrenalectomy
Study NCT02039765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate
Study NCT03263325 — intervention group
Intervention type: OTHER
Intervention: Discarded urine sample
Description: Collection of discarded urine during surgery and following surgery
Study NCT01960283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (Novatrex ®) + anti-H1
Description: Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.
Study NCT01960283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + anti-H1
Description: Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.
Study NCT03634111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
Study NCT03634111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
Study NCT03634111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
Study NCT03634111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.25% 20 ml each side
Study NCT03634111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.25% 20 ml each side
Study NCT02100254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: View personal narrative informational video
Study NCT02100254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral intervention
Description: View fact-based informational video
Study NCT03961191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation
Description: DNA methylation for the cervical cytology
Study NCT03961191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: high-risk HPV
Description: High-risk HPV testing for the cervical cytology
Study NCT03961191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TCT
Description: Thin prep liquid-based cytology test for the cervical cytology
Study NCT04378101 — intervention group
Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
Study NCT02229981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC294640
Study NCT02432937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corever
Description: Corever
Study NCT01696773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tangerine tomato juice
Description: Post-prandial feeding study
Study NCT01696773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red tomato juice
Description: Post-prandial feeding study
Study NCT01694433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: 1g daily BID
Study NCT01694433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g daily BID
Study NCT03925272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of samples (blood, stool, etc.)
Study NCT03925272 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic determinants analysis
Study NCT03925272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample obtained after surgery performed in the context of care
Study NCT04105686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ready to feed infant formula, feed ad libitum
Study NCT04105686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ready to feed infant formula, feed ad libitum
Study NCT03154255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Diet Educational Training
Description: The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose.
Study NCT04094324 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 4 questionnaires will be answered via iPads
Study NCT02776683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502
Study NCT02776683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Study NCT02507596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nano-crystalline hydroxyapatite silica gel
Description: it is a type of synthetic bone graft.
Study NCT02507596 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: open flap debridement
Description: a periodontal surgical procedure for the purpose of debridement.
Study NCT00506402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Capsule, 30 mg and 100 mg, BID, continuous dosing